Reply to Alessia Cimadamore, Liang Cheng, Marina Scarpelli, et al’s Letter to the Editor re: Alfonso Gómez de Liaño Lista, Nick van Dijk, Guillermo de Velasco Oria de Rueda, et al. Clinical Outcome After Progressing to Frontline and Second-line Anti–PD-1/PD-L1 in Advanced Urothelial Cancer. Eur Urol 2020;77:269–76. Progression and Hyperprogression Versus Pseudoprogression: Morphologic Documentation

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European urology 2021-01, Vol.79 (1), p.e20-e21
Hauptverfasser:	van Dijk, Nick, Gómez de Liaño Lista, Alfonso, Szabados, Bernadett, Powles, Thomas, van der Heijden, Michiel S.
Format:	Artikel
Sprache:	eng
Schlagworte:	B7-H1 Antigen Carcinoma, Transitional Cell Disease Progression Documentation Humans Male Prostatic Neoplasms
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page	e21
container_issue	1
container_start_page	e20
container_title	European urology
container_volume	79
creator	van Dijk, Nick Gómez de Liaño Lista, Alfonso Szabados, Bernadett Powles, Thomas van der Heijden, Michiel S.
description
doi_str_mv	10.1016/j.eururo.2020.10.018
format	Article
fullrecord	<record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2458037046</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0302283820308071</els_id><sourcerecordid>2458037046</sourcerecordid><originalsourceid>FETCH-LOGICAL-c311t-e39200be301e07a3dfb2334d789a78a4e405f4cfb99d709165a38f3c916d9b613</originalsourceid><addsrcrecordid>eNp9Ustu1DAUDQhEh8IfIHSXLCapHedZJKTR9IU0pVVLu4089s3U0yQebKdSWfUfWPUzEJ_QP-mX4HQKdMXGj-Pjc861bxC8oySihGZbywh70xsdxSQeoIjQ4nkwokXOwjzNyItgRBiJw7hgxUbw2tolIYSlJXsVbDBGU1bQdPTs9gRXzTU4DZMGrVUcpqrlkrfa4BhmincLmF5gtxjDITeq43AquFlh06gxoAPe3N_cWpihc2gGGXeBsCuV0wYMbnvVWndWw_7drxa_g8RB8-6n9pN1fAxflLiEK97BjlpejmG_V02DptUD8xwbboWGI-Nj-f1Jj5I_ukYwbVSnBG_gqHdCtwiTeohwbPTCDJX44D7OntGd80wE3kk4RaE7GT7sJ51T9zc_jndCuuWHGQXVwUT6LAIlnBntK2mU158OiIlgtzcD3MDw4B_zfDvOSi-QZ9E_U909-Bxcr9CsnoDnaGxv4dhiL_WTg2041GZ1oRu9UAJ2tOhb7Bx3_uhN8LLmjcW3j_NmcLa3-3V6EM6O9j9PJ7NQMEpdiKyMCZkjIxRJzpms5zFjicyLkucFTzAhaZ2Iel6WMiclzVLOipoJv5LlPKNsM_iw1vWxvvVoXdUqK_wH8w51b6s4SQvCcpJknpqsqcJoaw3W1cr4bjHXFSXV0JTVslo3ZTW80YD6pvTX3j869PMW5d9Lf7rQEz6tCejrvFJoKisUDv-gDApXSa3-7_Ab2br8vQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2458037046</pqid></control><display><type>article</type><title>Reply to Alessia Cimadamore, Liang Cheng, Marina Scarpelli, et al’s Letter to the Editor re: Alfonso Gómez de Liaño Lista, Nick van Dijk, Guillermo de Velasco Oria de Rueda, et al. Clinical Outcome After Progressing to Frontline and Second-line Anti–PD-1/PD-L1 in Advanced Urothelial Cancer. Eur Urol 2020;77:269–76. Progression and Hyperprogression Versus Pseudoprogression: Morphologic Documentation</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>van Dijk, Nick ; Gómez de Liaño Lista, Alfonso ; Szabados, Bernadett ; Powles, Thomas ; van der Heijden, Michiel S.</creator><creatorcontrib>van Dijk, Nick ; Gómez de Liaño Lista, Alfonso ; Szabados, Bernadett ; Powles, Thomas ; van der Heijden, Michiel S.</creatorcontrib><identifier>ISSN: 0302-2838</identifier><identifier>EISSN: 1873-7560</identifier><identifier>DOI: 10.1016/j.eururo.2020.10.018</identifier><identifier>PMID: 33153815</identifier><language>eng</language><publisher>Switzerland: Elsevier B.V</publisher><subject>B7-H1 Antigen ; Carcinoma, Transitional Cell ; Disease Progression ; Documentation ; Humans ; Male ; Prostatic Neoplasms</subject><ispartof>European urology, 2021-01, Vol.79 (1), p.e20-e21</ispartof><rights>2020 European Association of Urology</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c311t-e39200be301e07a3dfb2334d789a78a4e405f4cfb99d709165a38f3c916d9b613</cites><orcidid>0000-0002-1844-8474 ; 0000-0001-5115-5086</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.eururo.2020.10.018$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33153815$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>van Dijk, Nick</creatorcontrib><creatorcontrib>Gómez de Liaño Lista, Alfonso</creatorcontrib><creatorcontrib>Szabados, Bernadett</creatorcontrib><creatorcontrib>Powles, Thomas</creatorcontrib><creatorcontrib>van der Heijden, Michiel S.</creatorcontrib><title>Reply to Alessia Cimadamore, Liang Cheng, Marina Scarpelli, et al’s Letter to the Editor re: Alfonso Gómez de Liaño Lista, Nick van Dijk, Guillermo de Velasco Oria de Rueda, et al. Clinical Outcome After Progressing to Frontline and Second-line Anti–PD-1/PD-L1 in Advanced Urothelial Cancer. Eur Urol 2020;77:269–76. Progression and Hyperprogression Versus Pseudoprogression: Morphologic Documentation</title><title>European urology</title><addtitle>Eur Urol</addtitle><subject>B7-H1 Antigen</subject><subject>Carcinoma, Transitional Cell</subject><subject>Disease Progression</subject><subject>Documentation</subject><subject>Humans</subject><subject>Male</subject><subject>Prostatic Neoplasms</subject><issn>0302-2838</issn><issn>1873-7560</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9Ustu1DAUDQhEh8IfIHSXLCapHedZJKTR9IU0pVVLu4089s3U0yQebKdSWfUfWPUzEJ_QP-mX4HQKdMXGj-Pjc861bxC8oySihGZbywh70xsdxSQeoIjQ4nkwokXOwjzNyItgRBiJw7hgxUbw2tolIYSlJXsVbDBGU1bQdPTs9gRXzTU4DZMGrVUcpqrlkrfa4BhmincLmF5gtxjDITeq43AquFlh06gxoAPe3N_cWpihc2gGGXeBsCuV0wYMbnvVWndWw_7drxa_g8RB8-6n9pN1fAxflLiEK97BjlpejmG_V02DptUD8xwbboWGI-Nj-f1Jj5I_ukYwbVSnBG_gqHdCtwiTeohwbPTCDJX44D7OntGd80wE3kk4RaE7GT7sJ51T9zc_jndCuuWHGQXVwUT6LAIlnBntK2mU158OiIlgtzcD3MDw4B_zfDvOSi-QZ9E_U909-Bxcr9CsnoDnaGxv4dhiL_WTg2041GZ1oRu9UAJ2tOhb7Bx3_uhN8LLmjcW3j_NmcLa3-3V6EM6O9j9PJ7NQMEpdiKyMCZkjIxRJzpms5zFjicyLkucFTzAhaZ2Iel6WMiclzVLOipoJv5LlPKNsM_iw1vWxvvVoXdUqK_wH8w51b6s4SQvCcpJknpqsqcJoaw3W1cr4bjHXFSXV0JTVslo3ZTW80YD6pvTX3j869PMW5d9Lf7rQEz6tCejrvFJoKisUDv-gDApXSa3-7_Ab2br8vQ</recordid><startdate>202101</startdate><enddate>202101</enddate><creator>van Dijk, Nick</creator><creator>Gómez de Liaño Lista, Alfonso</creator><creator>Szabados, Bernadett</creator><creator>Powles, Thomas</creator><creator>van der Heijden, Michiel S.</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-1844-8474</orcidid><orcidid>https://orcid.org/0000-0001-5115-5086</orcidid></search><sort><creationdate>202101</creationdate><title>Reply to Alessia Cimadamore, Liang Cheng, Marina Scarpelli, et al’s Letter to the Editor re: Alfonso Gómez de Liaño Lista, Nick van Dijk, Guillermo de Velasco Oria de Rueda, et al. Clinical Outcome After Progressing to Frontline and Second-line Anti–PD-1/PD-L1 in Advanced Urothelial Cancer. Eur Urol 2020;77:269–76. Progression and Hyperprogression Versus Pseudoprogression: Morphologic Documentation</title><author>van Dijk, Nick ; Gómez de Liaño Lista, Alfonso ; Szabados, Bernadett ; Powles, Thomas ; van der Heijden, Michiel S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c311t-e39200be301e07a3dfb2334d789a78a4e405f4cfb99d709165a38f3c916d9b613</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>B7-H1 Antigen</topic><topic>Carcinoma, Transitional Cell</topic><topic>Disease Progression</topic><topic>Documentation</topic><topic>Humans</topic><topic>Male</topic><topic>Prostatic Neoplasms</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>van Dijk, Nick</creatorcontrib><creatorcontrib>Gómez de Liaño Lista, Alfonso</creatorcontrib><creatorcontrib>Szabados, Bernadett</creatorcontrib><creatorcontrib>Powles, Thomas</creatorcontrib><creatorcontrib>van der Heijden, Michiel S.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European urology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>van Dijk, Nick</au><au>Gómez de Liaño Lista, Alfonso</au><au>Szabados, Bernadett</au><au>Powles, Thomas</au><au>van der Heijden, Michiel S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Reply to Alessia Cimadamore, Liang Cheng, Marina Scarpelli, et al’s Letter to the Editor re: Alfonso Gómez de Liaño Lista, Nick van Dijk, Guillermo de Velasco Oria de Rueda, et al. Clinical Outcome After Progressing to Frontline and Second-line Anti–PD-1/PD-L1 in Advanced Urothelial Cancer. Eur Urol 2020;77:269–76. Progression and Hyperprogression Versus Pseudoprogression: Morphologic Documentation</atitle><jtitle>European urology</jtitle><addtitle>Eur Urol</addtitle><date>2021-01</date><risdate>2021</risdate><volume>79</volume><issue>1</issue><spage>e20</spage><epage>e21</epage><pages>e20-e21</pages><issn>0302-2838</issn><eissn>1873-7560</eissn><cop>Switzerland</cop><pub>Elsevier B.V</pub><pmid>33153815</pmid><doi>10.1016/j.eururo.2020.10.018</doi><orcidid>https://orcid.org/0000-0002-1844-8474</orcidid><orcidid>https://orcid.org/0000-0001-5115-5086</orcidid></addata></record>
fulltext	fulltext
identifier	ISSN: 0302-2838
ispartof	European urology, 2021-01, Vol.79 (1), p.e20-e21
issn	0302-2838 1873-7560
language	eng
recordid	cdi_proquest_miscellaneous_2458037046
source	MEDLINE; Elsevier ScienceDirect Journals Complete
subjects	B7-H1 Antigen Carcinoma, Transitional Cell Disease Progression Documentation Humans Male Prostatic Neoplasms
title	Reply to Alessia Cimadamore, Liang Cheng, Marina Scarpelli, et al’s Letter to the Editor re: Alfonso Gómez de Liaño Lista, Nick van Dijk, Guillermo de Velasco Oria de Rueda, et al. Clinical Outcome After Progressing to Frontline and Second-line Anti–PD-1/PD-L1 in Advanced Urothelial Cancer. Eur Urol 2020;77:269–76. Progression and Hyperprogression Versus Pseudoprogression: Morphologic Documentation
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T12%3A27%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Reply%20to%20Alessia%20Cimadamore,%20Liang%20Cheng,%20Marina%20Scarpelli,%20et%20al%E2%80%99s%20Letter%20to%20the%20Editor%20re:%20Alfonso%20G%C3%B3mez%20de%20Lia%C3%B1o%20Lista,%20Nick%20van%20Dijk,%20Guillermo%20de%20Velasco%20Oria%20de%20Rueda,%20et%20al.%20Clinical%20Outcome%20After%20Progressing%20to%20Frontline%20and%20Second-line%20Anti%E2%80%93PD-1/PD-L1%20in%20Advanced%20Urothelial%20Cancer.%20Eur%20Urol%202020;77:269%E2%80%9376.%20Progression%20and%20Hyperprogression%20Versus%20Pseudoprogression:%20Morphologic%20Documentation&rft.jtitle=European%20urology&rft.au=van%20Dijk,%20Nick&rft.date=2021-01&rft.volume=79&rft.issue=1&rft.spage=e20&rft.epage=e21&rft.pages=e20-e21&rft.issn=0302-2838&rft.eissn=1873-7560&rft_id=info:doi/10.1016/j.eururo.2020.10.018&rft_dat=%3Cproquest_cross%3E2458037046%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2458037046&rft_id=info:pmid/33153815&rft_els_id=S0302283820308071&rfr_iscdi=true